Larvol Delta - Aprea-Therapeutics-Announces-Additional-Positive-Clinical-Activity-for-WEE1-Inhibitor-APR1051-Including-Second-Partial-Response-in-Ongoing-ACESOT1051-Trial

APR-1051 - Aprea

https://www.globenewswire.com/news-release/2026/02/18/3240156/0/en/Aprea-Therapeutics-Announces-Additional-Positive-Clinical-Activity-for-WEE1-Inhibitor-APR-1051-Including-Second-Partial-Response-in-Ongoing-ACESOT-1051-Trial.html

Feb 18, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next